跳至主要内容
临床试验/NCT01693354
NCT01693354Unknown不适用

Mid-dilution Hemodiafiltration International Randomized Prospective Study on Incident Patients Focused on Outcome

IRCCS Azienda Ospedaliero-Universitaria di Bologna8 个研究点 分布在 4 个国家目标入组 500 人开始时间: 2012年9月最近更新:
适应症

试验速览

阶段
不适用
入组人数
500
试验地点
8
主要终点
crude, all-causes mortality

研究概览

简要总结

The purpose of this study is to determine whether mid-dilution hemodiafiltration is effective in the reduction of the crude mortality risk in patients who have been undergoing renal replacement treatment for less than 1 year. Patients will be randomized since the beginning of the study in two groups: standard HF dialysis and mid-dilution HDF.

详细描述

It is a matter of fact that in the last decades the Chronic Kidney Disease (CKD) population has widely changed. In Italy, for example, more than 50% of the incident dialysis patients are more than 70 year old, with diabetic and hypertension being the major underlying diseases; moreover a great percentage of the patients starts dialysis with a burden of at least 1-2 comorbidities [1]. Online hemodiafiltration (online HDF) has been recently associated with better patient survival in comparison with standard hemodialysis in two large trials [2,3]; the overall relative risk of mortality was found to be approximately 33% lower in patients treated with online HDF [2,3]. These impressive results were not obtained anyway on the whole population, but in a sub-group analysis. A strong correlation was found between the total convective volume obtained and the mortality risk reduction; HDF was found to be significantly better than standard hemodialysis when a total convective volume of 19-22 L/session (in 4 hours sessions of post-dilution HDF) was achieved.

These results support the importance of the "adequate convective dose" concept in order to improve the patient outcomes especially in frail patients, as recently demonstrated by a large randomised control trial, the MPO study [4], comparing High Flux versus Low Flux dialysis in patients with plasma albumin levels equal to or less than 4 gr/dl ( as a marker of patient comorbidities) and, in a post hoc analysis, in diabetic patients [4].

Mid-dilution HDF is a variant of classical HDF combining simultaneous pre- and post.-dilution in order to maximise middle and large solutes removal.

The MILESTONE study would aim to fully demonstrate for mid-dilution HDF the significant mortality risk reduction observed in the recent mentioned studies.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • On a thrice/week RRT for at least 3 months
  • Dialysis vintage > 3 months
  • Signed informed consent
  • Blood flow > 300 mL/min

排除标准

  • On waiting list for living-donor transplant
  • Residual diuresis > 500 mL/day
  • Inability, as judget by the investigator, to follow or understand the protocol instructions
  • Active neoplastic disease
  • Single needle treatment
  • Patients with expectancy life lower than 6 months
  • Inclusion to other studies
  • Pregnancy

结局指标

主要结局

crude, all-causes mortality

时间窗: 5 years

The primary objective will be assessed by the incidence rate of fatal events

次要结局

  • Micro-inflammation evaluation(1 year)
  • Cardiovascular morbidity(5 years)
  • Nutrition and anaemia management(1 year)
  • Quality of life and dialysis tolerance evaluated by questionnaire(1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Antonio Santoro

Professor Antonio Santoro MD, Chief of Nephrology

IRCCS Azienda Ospedaliero-Universitaria di Bologna

研究点 (8)

Loading locations...

相似试验